HUTCHMED Commences the P-II/III Study of Surufatinib Plus Camrelizumab for Pancreatic Ductal Adenocarcinoma
Shots:
- HUTCHMED has commenced the P-II/III study of its surufatinib (angio-immuno kinase inhibitor) combined with Jiangsu Hengrui’s camrelizumab (PD-1 antibody) for pancreatic ductal adenocarcinoma (PDAC) in China with the first patient dosed on May 08, 2024
- The P-II/III study investigates the safety & efficacy of surufatinib (oral) in addition to camrelizumab, nab-paclitaxel & gemcitabine vs nab-paclitaxel + gemcitabine for the 1L treatment of metastatic pancreatic cancer adults (n=500) who did not receive prior systemic anti-tumor therapy
- The 1EP of the study includes OS while other endpoints are ORR, PFS, DCR, quality of life, duration of response and time to response
Ref: HUTCHMED | Image: HUTCHMED
Related News:- The US FDA Issued Complete Response Letter to Hutchmed’s Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
